Delivery Order SPE2DB22D3016-SPE2DB25FBKB2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,178.52 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injections on June 24, 2025, with completion targeted for June 25, 2025. This competitively awarded, firm fixed-price delivery order represents fulfillment under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections with a ceiling value of $7,625.80. This competitively awarded, firm fixed-price contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The delivery order is scheduled for completion by August 5, 2025, with...
- The Defense Logistics Agency awarded a delivery order valued at $1,096.88 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 14, 2025. The contract is classified as firm fixed price with an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, reflecting the company's capability to meet...
- The Defense Logistics Agency awarded a delivery order valued at $9,927.33 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's substantial role as a critical pharmaceutical supplier to the federal government. The order will be fulfilled from the contractor's location in Conshohocken,...
- The Defense Logistics Agency awarded a $2,383.56 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injections. This non-competitive delivery order, with an ultimate completion date of July 15, 2025, represents a small-value pharmaceutical transaction supporting federal medical procurement needs. The award was fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $10,016.78 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections. This firm fixed price contract, with an ultimate completion date of September 8, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $1,584.34 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pens. This firm fixed-price, non-competitive delivery order is set to be completed by August 19, 2025, with performance occurring at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government's...
- The Defense Logistics Agency awarded a $10,814.13 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injectors with a completion date of June 2, 2025. This non-set-aside competitive award represents a continuation of services under AmerisourceBergen's broader pharmaceutical supply arrangement with the federal government. The delivery order is being fulfilled from the company's place of business in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,048.25 for Zepbound 10 mg/0.5 mL pen injectors on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's extensive pharmaceutical supply...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,389.28 for Zepbound 2.5 mg/0.5 mL pen injections, with a performance location in Conshohocken, Pennsylvania and an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under a larger vehicle within the federal pharmaceutical supply chain supporting military and defense healthcare needs....
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBKB2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,822.99 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injections on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. The company's significant contract portfolio with DLA demonstrates its established capability to meet federal pharmaceutical procurement requirements across multiple therapeutic domains, from specialty medications to vaccines and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 9/18/25 |